Beatrix Bálint

2.1k citations
29 papers · 1.5k · 1 hit paper · h-index 16

Impact in

    • Lung Cancer Treatments and Mutations
    • Chronic Obstructive Pulmonary Disease (COPD) Research
    • Respiratory and Cough-Related Research
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies

Papers in

    • Lung Cancer Treatments and Mutations 14
    • Chronic Obstructive Pulmonary Disease (COPD) Research 6
    • Lung Cancer Diagnosis and Treatment 3
    • Colorectal Cancer Treatments and Studies 6
    • Lung Cancer Research Studies 5

Beatrix Bálint

29 papers receiving 1.4k citations

Beatrix Bálint's Hit Papers

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial 2015 · 331 citations
3310+3+7Years since publication100200300

Peers

Beatrix Bálint
Comparison fields: 5 of 102
  • Pulmonary and Respiratory Medicine 941
  • Oncology 554
  • Physiology 395
  • Immunology and Allergy 84
  • Cancer Research 164
Replace Kozo Kuribayashi with:
Kozo Kuribayashi Japan
Shaoli Zhang China
Christian Geßner Germany
Erik Vegt Netherlands
Ming-Shyan Huang Taiwan
Annette Fisseler‐Eckhoff Germany
Veli‐Matti Kosma Finland
Jean‐Marc Bertho France
Jiaxin Zhou China
Zhong‐Ying Shen China
Beatrix Bálint relative to Kozo Kuribayashi Japan Kozo Kuribayashi's profile →
Citations per field
00.5×2.6×
Kozo Kuribayashi · 1×
Citations per year

Countries citing papers authored by Beatrix Bálint

Since Specialization
Citations

This map shows the geographic impact of Beatrix Bálint's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatrix Bálint with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatrix Bálint more than expected).

Fields of papers citing papers by Beatrix Bálint

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatrix Bálint. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatrix Bálint. The network helps show where Beatrix Bálint may publish in the future.

Co-authors

The 25 scholars most cited alongside Beatrix Bálint, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Beatrix Bálint Line = papers co-authored together Beatrix Bálint links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2010365
2
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Hit paper breakdown →
2015331
3 2002157
4 2001115
5 200196
6 201573
7 201358
8 201244
9 200337
10 201435
11 200128
12 201426
13 201223
14 201122
15 200817
16 201715
17 201310
18 20079
19
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
20107
20 20184

About Beatrix Bálint

Beatrix Bálint is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Physiology, Health, Toxicology and Mutagenesis and Immunology and Allergy, having authored 29 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), Asthma and respiratory diseases (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers), Allergic Rhinitis and Sensitization (5 papers), Lung Cancer Research Studies (5 papers), Air Quality and Health Impacts (5 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (941 citations), Oncology (554 citations), Physiology (395 citations), Immunology and Allergy (84 citations) and Cancer Research (164 citations). Beatrix Bálint has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Sergei A. Kharitonov, Peter J. Barnes, Martin Reck, Andrew Bush, Nicola Wilson, Zsuzsanna Csoma, Louise Donnelly, Luis Paz‐Ares, Rodryg Ramlau and László Makra. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Thorax and International Journal of Biometeorology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact